NCT06967961Recruiting
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
Source: ClinicalTrials.gov · Last updated 15 Jun 2026
Brief summary (registry, in English)
A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis. Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer. 450 patients will be enrolled in total.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 450 (estimated)
- First submitted
- 5 May 2025
- Start date
- 23 Jul 2025
- Primary completion date
- 23 Jul 2029
- Lead sponsor
- Institut Claudius Regaud
- Diseases
- Prostate cancer, Kidney cancer, Bladder cancer, Melanoma, Cervical cancer, Sarcoma
- NCT number
- NCT06967961
What you commit to
- Study type: Interventional
- Planned participants: 450
- From 23 Jul 2025 to the primary completion date, 23 Jul 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 1\. Patient with localized disease.
- 3\. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol.
Other
- 2\. Pregnant or breast-feeding women.
- 4\. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
Who the study is looking for
- 1\. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors
- 2\. Metastatic disease for which the treatment (whatever the line) has not been initiated yet
- 3\. Age ≥ 18 years
- 4\. Patient affiliated to a French Social Security scheme
- 5\. Patient having signed his/her informed consent prior to inclusion in the study and prior to any specific procedure for the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oncopole Claudius Regaud, IUCT-O Coordinator of this site? Confirm its status | Toulouse | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.